東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back to Search results for [ null ]

Switch To: Labeled | MARC Mode | ISBD

Corporate R&D Investments following ...

Zhang, Yue.

Linked to FindBook

Google Book

Amazon

博客來

Corporate R&D Investments following Competitors' Disclosures: Evidence from the Drug Development Process.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Corporate R&D Investments following Competitors' Disclosures: Evidence from the Drug Development Process./
Author:	Zhang, Yue.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2020,
Description:	71 p.
Notes:	Source: Dissertations Abstracts International, Volume: 82-06, Section: A.
Contained By:	Dissertations Abstracts International82-06A.
Subject:	Finance. -
Online resource:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27999994
ISBN:	9798678119094

Corporate R&D Investments following Competitors' Disclosures: Evidence from the Drug Development Process.
Zhang, Yue.

Corporate R&D Investments following Competitors' Disclosures: Evidence from the Drug Development Process. - Ann Arbor : ProQuest Dissertations & Theses, 2020 - 71 p.

Source: Dissertations Abstracts International, Volume: 82-06, Section: A.

Thesis (Ph.D.)--University of Pittsburgh, 2020.

This item must not be sold to any third party vendors.

This dissertation studies the role of peer disclosures in shaping corporate R&D investments. Using the online registration of clinical trials in the drug development process, I find that a firm's R&D investments are deterred by disclosures of clinical trial initiation from strong rivals but encouraged by disclosures from weak rivals. The cross-sectional analyses suggest that the deterrence effect of peer disclosure is stronger when the therapeutic area has a high clinical-trial success rate, the encouragement effect is stronger when the market has fewer competing firms, and both effects are strengthened when the focal firm has a diversified R&D portfolio. Overall, my findings suggest that the way a firm reacts to peer disclosure varies with the disclosing firms' relative competitiveness in the R&D race.

ISBN: 9798678119094Subjects--Topical Terms:

542899
Finance.
Subjects--Index Terms:

Clinical trials

Corporate R&D Investments following Competitors' Disclosures: Evidence from the Drug Development Process.
LDR:02052nmm a2200385 4500 001 2276139
005 20210427130824.5
008 220723s2020 ||||||||||||||||| ||eng d
020 $a 9798678119094
035 $a (MiAaPQ)AAI27999994
035 $a AAI27999994
040 $a MiAaPQ $c MiAaPQ
100 1 $a Zhang, Yue. $3 1297056
245 1 0 $a Corporate R&D Investments following Competitors' Disclosures: Evidence from the Drug Development Process.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2020
300 $a 71 p.
500 $a Source: Dissertations Abstracts International, Volume: 82-06, Section: A.
500 $a Advisor: Evans, John Harry, III;Feng, Mei.
502 $a Thesis (Ph.D.)--University of Pittsburgh, 2020.
506 $a This item must not be sold to any third party vendors.
520 $a This dissertation studies the role of peer disclosures in shaping corporate R&D investments. Using the online registration of clinical trials in the drug development process, I find that a firm's R&D investments are deterred by disclosures of clinical trial initiation from strong rivals but encouraged by disclosures from weak rivals. The cross-sectional analyses suggest that the deterrence effect of peer disclosure is stronger when the therapeutic area has a high clinical-trial success rate, the encouragement effect is stronger when the market has fewer competing firms, and both effects are strengthened when the focal firm has a diversified R&D portfolio. Overall, my findings suggest that the way a firm reacts to peer disclosure varies with the disclosing firms' relative competitiveness in the R&D race.
590 $a School code: 0178.
650 4 $a Finance. $3 542899
653 $a Clinical trials
653 $a Corporate disclosure
653 $a Drug development
653 $a Innovation
653 $a Product market competition
653 $a R&D
690 $a 0272
690 $a 0501
690 $a 0508
710 2 $a University of Pittsburgh. $b Joseph M. Katz Graduate School of Business. $3 3542311
773 0 $t Dissertations Abstracts International $g 82-06A.
790 $a 0178
791 $a Ph.D.
792 $a 2020
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=27999994